jaks

Cerdulatinib (PRT2070) 是一种选择性 Tyk2抑制剂，IC50为 0.5 nM。它是 JAK 和 SYK 的双抑制剂，抑制JAK1、2、3 和SYK 的IC50分别为12、6、8 和 32。

Oclacitinib (PF-03394197) 是一种有效的选择性 JAKs 抑制剂，IC50 为 10-99 nM；不抑制一组 38 种非 JAK 激酶 (IC50 > 1000 nM)。

JAK-STAT-IN-1 是一种特异性 JAK-STAT 抑制剂，适用于研究自身免疫性疾病。

JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM and demonstrating a 246-fold selectivity compared to other JAKs.

Brevilin A 是从Centipeda minima 中分离的倍半萜内酯，具有抗癌活性。它通过线粒体途径和 PI3K/AKT/mTOR 失活诱导结肠腺癌细胞 CT26 的凋亡和自噬。它是一种选择性JAK-STAT 信号通路抑制剂，通过减弱 JAK 信号和 阻塞 STAT3 信号起作用。

Ritlecitinib, also known as PF-06651600, is a potent and selective JAK3 inhibitor. PF-06651600 is a potent and low clearance compound with demonstrated in vivo efficacy. The favorable efficacy and safety profile of this JAK3-specific inhibitor PF-06651600 led to its evaluation in several human clinical studies. JAK3 was among the first of the JAKs targeted for therapeutic intervention due to the strong validation provided by human SCID patients displaying JAK3 deficiencies.

Tofacitinib maleate, also known as tasocitinib, CP-690550, is a Janus kinase (JAK) inhibitor. Tofacitinib maleate modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through pairing of JAKs (e.g., JAK1/JAK3, JAK1/JAK2, JAK1/TyK2, JAK2/JAK2). Tofacitinib maleate inhibited the in vitro activities of JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 combinations with IC50 of 406, 56, and 1377 nM, respectively.

Tofacitinib HCl, also known as tasocitinib, CP-690550, is a Janus kinase (JAK) inhibitor. Tofacitinib HCl modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through pairing of JAKs (e.g., JAK1/JAK3, JAK1/JAK2, JAK1/TyK2, JAK2/JAK2). Tofacitinib HCl inhibited the in vitro activities of JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 combinations with IC50 of 406, 56, and 1377 nM, respectively.

JAK-IN-30（化合物31）是一种具有水溶性的JAK抑制剂，对JAK2、JAK1、JAK3及TYK2的IC50值分别为2、15、18及2 nM。该化合物作为研究干眼症（DED）的潜在药物而备受关注。

Brevilin A (Standard) 是 Brevilin A 的标准品。适用于定量分析、质量控制及生化实验等相关研究。Brevilin A 是从Centipeda minima 中分离的倍半萜内酯，具有抗癌活性。它通过线粒体途径和 PI3K/AKT/mTOR 失活诱导结肠腺癌细胞 CT26 的凋亡和自噬。它是一种选择性JAK-STAT 信号通路抑制剂，通过减弱 JAK 信号和 阻塞 STAT3 信号起作用。